Ann: Interim NOX66 Radiotherapy Clinical Data, page-5

I have to apologize Roger10, I was being facetious . Even a 25% response rate is amazing and should have the market on fire, according to early NOX anns and presentations. A 50% rate being claimed via that narrative is close to miraculous. My point is it seem the markets reaction is skeptical or perhaps just doesn't believe it. Or perhaps the narrative is wrong?

"A phase I/II clinical study of 34 patients with metastatic castration-resistant prostate cancer treated with ipilimumab and 8 Gy fractions on up to three bone metastases reported a complete response in one patient, stable disease in six patients, and prostate-specific antigen declines of ≥50% [41]. Golden et al. recently completed a study of the abscopal effect after administering GM-CSF along with 3.5 Gy × 10 to patients with metastatic solid tumors [42•]. The group reported abscopal responses in 11 of the 41 enrolled patients. Of note, 5 of 14 breast cancer patients had an abscopal response.
"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346418/